Last updated: February 24, 2026
What is NDC 61269-0403?
NDC 61269-0403 refers to Kybella (deoxycholic acid) injection, used for submental fat reduction. It received FDA approval in 2015 for adult patients with moderate to severe fat beneath the chin.
Market Size and Competitive Landscape
Key Market Drivers
- Rising demand for minimally invasive aesthetic procedures.
- Increasing prevalence of obesity and overweight conditions.
- Growing acceptance of non-surgical fat removal treatments.
Target Population Estimate
- U.S. adult population with submental fat estimated at approximately 20 million.
- Eligible candidates (moderate to severe submental fat): roughly 10 million.
Major Competitors
- Kybella (Allergen/Revance)
- Off-label devices (Liposuction, CoolSculpting)
- Alternative injectable treatments in early development
Market Penetration
- As of 2022, Kybella held approximately 78% of the injectable fat reduction market globally.
- The U.S. accounts for over 70% of this market.
- Kybella was administered in around 600,000 procedures in 2022 in the U.S.
Pricing Data
Current Pricing Metrics
- Average treatment sessions per patient: 2-4.
- Price per vial: approximately $600 to $850.
- Cost per treatment session: $1,200 to $3,400 depending on doses.
Market Pricing Strategies
- Kybella's per-treatment cost varies based on severity.
- Pricing across clinics can range from $500 to $900 per vial.
- Treatment bundle prices are often offered, averaging $1,500 to $3,500 per session.
Revenue Estimations
- Average revenue per patient: around $2,000 to $4,000.
- Market revenue in the U.S. (2022): estimated $1.2 billion.
- Potential for global market expansion could drive sales to $2 billion by 2025, assuming continued adoption.
Price Projection Trends
| Year |
Estimated Price Range per Vial |
Notes |
| 2023 |
$650 - $850 |
Stable, with slight discounts in high-volume clinics |
| 2024 |
$600 - $800 |
Competitive pricing pressure; possible discounts to increase market share |
| 2025 |
$550 - $750 |
Further price erosion due to increased competition and economies of scale |
Factors Influencing Future Pricing
- Entry of biosimilar or alternative injectable products.
- Changes in regulatory landscape affecting reimbursement.
- Expansion into new markets with different pricing expectations.
- Adoption rate acceleration or deceleration owing to aesthetic trends.
Regulatory and Reimbursement Outlook
- Kybella reimbursed through commercial insurers; reimbursement rates vary.
- CMS has yet to broadly reimburse for aesthetic procedures; most funding comes from out-of-pocket payments.
- Future reimbursement policies could impact price stabilization or reductions.
Key Takeaways
- The injectable fat reduction market is mature but still expanding, with Kybella as the dominant product.
- Pricing remains stable but faces potential downward pressure from competitors and biosimilars.
- Market size and revenue are expected to grow, primarily driven by increasing demand in the U.S.
- Price projections indicate slight decreases per vial to accommodate market competition and consumer affordability.
FAQs
1. What is the primary use of NDC 61269-0403?
It is used to reduce submental fat in adults.
2. How many treatments are typically required?
Most patients undergo 2-4 sessions.
3. What is the average treatment cost?
Between $1,500 and $3,500 per session, depending on the number of vials used.
4. What are the main competitors?
Other injectable fat reduction products and non-invasive devices like CoolSculpting and Liposuction.
5. How will prices likely change over the next three years?
Prices per vial are projected to decline slightly, from around $850 to $750 by 2025.
Citations
- FDA. (2015). Approval of Kybella for submental fat reduction.
- IQVIA. (2022). Aesthetic procedure market report.
- American Society for Aesthetic Plastic Surgery. (2022). Procedure statistics report.
- MarketWatch. (2023). Fat reduction market size and forecast.
- CMS. (2023). Reimbursement overview for aesthetic procedures.
